MedTrace Logo

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

NCT01352338 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2016-02-26

No results posted yet for this study

Summary

Study Phase: phase 1 and phase 2

Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide

Study design: prospective, multicenter, non-randomized

Conditions

Interventions

DRUG

Lenalidomide, endoxan, prednisone

dose-finding

DRUG

lenalidomide, endoxan, prednisone

oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Dr. N.C.W.J. Donk, van de, MD PhD · UMC Utrecht

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-11-30
Completion
2016-02-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01352338 on ClinicalTrials.gov